Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fourteen analysts that are covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $52.56.

Several analysts have recently issued reports on KROS shares. Oppenheimer reduced their price objective on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research report on Thursday, January 16th. William Blair cut shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 12th. Guggenheim restated a "neutral" rating on shares of Keros Therapeutics in a report on Friday, January 17th. Piper Sandler reduced their price objective on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research note on Friday, January 17th. Finally, TD Cowen downgraded shares of Keros Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th.

Keros Therapeutics Price Performance

Keros Therapeutics stock traded down $0.66 during mid-day trading on Thursday, reaching $10.86. The company had a trading volume of 1,187,598 shares, compared to its average volume of 2,180,866. The stock's 50-day simple moving average is $22.31 and its 200-day simple moving average is $43.48. The company has a market capitalization of $439.94 million, a P/E ratio of -2.08 and a beta of 1.39. Keros Therapeutics has a 1 year low of $9.77 and a 1 year high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics's quarterly revenue was up 4750.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.33) earnings per share. On average, equities analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently made changes to their positions in the company. KBC Group NV grew its holdings in shares of Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after purchasing an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Keros Therapeutics in the 3rd quarter worth $89,000. AlphaQuest LLC lifted its holdings in Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after acquiring an additional 2,964 shares during the last quarter. Finally, LMR Partners LLP acquired a new stake in Keros Therapeutics during the third quarter valued at approximately $213,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.